BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 25804634)

  • 41. Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma.
    Saberi B; Garonzik-Wang J; Ma M; Ajayi T; Kim A; Luu H; Jakhete N; Pustavoitau A; Anders RA; Georgiades C; Kamel I; Ottmann S; Philosophe B; Cameron AM; Gurakar A
    Exp Clin Transplant; 2020 Aug; 18(4):463-469. PubMed ID: 30084757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-centre experience.
    Wehrle CJ; Raj R; Maspero M; Satish S; Eghtesad B; Pita A; Kim J; Khalil M; Calderon E; Orabi D; Zervos B; Modaresi Esfeh J; Whitsett Linganna M; Diago-Uso T; Fujiki M; Quintini C; Kwon CD; Miller C; Pinna A; Aucejo F; Hashimoto K; Schlegel A
    Int J Surg; 2024 May; 110(5):2818-2831. PubMed ID: 38241354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liver transplantation and expanded Milan criteria: does it really work?
    Ferreira MV; Chaib E; Nascimento MU; Nersessian RS; Setuguti DT; D'Albuquerque LA
    Arq Gastroenterol; 2012; 49(3):189-94. PubMed ID: 23011240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation.
    Teng F; Wang GH; Tao YF; Guo WY; Wang ZX; Ding GS; Shi XM; Fu ZR
    World J Gastroenterol; 2014 Aug; 20(31):10900-7. PubMed ID: 25152592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alpha-Fetoprotein as a Modifier of Anatomic Criteria for Transplantation of HCC Patients.
    Daoud A; Soliman K; Teeter L; Ali H; Graviss EA; Mogawer S; Sholkamy A; El-Shazli M; Gaber AO
    Transplant Proc; 2021 Apr; 53(3):833-838. PubMed ID: 33589231
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma.
    Andreou A; Gül S; Pascher A; Schöning W; Al-Abadi H; Bahra M; Klein F; Denecke T; Strücker B; Puhl G; Pratschke J; Seehofer D
    HPB (Oxford); 2015 Feb; 17(2):168-75. PubMed ID: 25263399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria.
    Zaydfudim VM; Vachharajani N; Klintmalm GB; Jarnagin WR; Hemming AW; Doyle MB; Cavaness KM; Chapman WC; Nagorney DM
    Ann Surg; 2016 Oct; 264(4):650-8. PubMed ID: 27433910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan or UCSF criteria.
    Jiang L; Yan LN; Wen TF; Li B; Yang JY
    Hepatobiliary Pancreat Dis Int; 2013 Oct; 12(5):494-9. PubMed ID: 24103279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
    Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
    J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
    Mazzaferro V; Citterio D; Bhoori S; Bongini M; Miceli R; De Carlis L; Colledan M; Salizzoni M; Romagnoli R; Antonelli B; Vivarelli M; Tisone G; Rossi M; Gruttadauria S; Di Sandro S; De Carlis R; Lucà MG; De Giorgio M; Mirabella S; Belli L; Fagiuoli S; Martini S; Iavarone M; Svegliati Baroni G; Angelico M; Ginanni Corradini S; Volpes R; Mariani L; Regalia E; Flores M; Droz Dit Busset M; Sposito C
    Lancet Oncol; 2020 Jul; 21(7):947-956. PubMed ID: 32615109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.
    Kim Y; Stahl CC; Makramalla A; Olowokure OO; Ristagno RL; Dhar VK; Schoech MR; Chadalavada S; Latif T; Kharofa J; Bari K; Shah SA
    Surgery; 2017 Dec; 162(6):1250-1258. PubMed ID: 29033224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liver transplantation for hepatocellular carcinoma within the Milan criteria versus the University of California San Francisco criteria: a comparative study.
    Abdelfattah MR; Elsiesy H; Al-Manea H; Broering DC
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):398-403. PubMed ID: 29280920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
    Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
    BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transplantation for Hepatocellular Carcinoma: Is There a Tumor Size Limit?
    Daoud A; Teeter L; Ghobrial RM; Graviss EA; Mogawer S; Sholkamy A; El-Shazli M; Gaber AO
    Transplant Proc; 2018 Dec; 50(10):3577-3581. PubMed ID: 30577241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of [
    Ye YF; Wang W; Wang T; Yu J; Geng L; Yu SF; Yan S; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):257-263. PubMed ID: 28603093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.
    Duffy JP; Vardanian A; Benjamin E; Watson M; Farmer DG; Ghobrial RM; Lipshutz G; Yersiz H; Lu DS; Lassman C; Tong MJ; Hiatt JR; Busuttil RW
    Ann Surg; 2007 Sep; 246(3):502-9; discussion 509-11. PubMed ID: 17717454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant.
    Rahatli S; Ayvazoglu Soy EH; Oguz A; Altundag O; Moray G; Haberal M
    Exp Clin Transplant; 2020 Apr; 18(2):201-205. PubMed ID: 32279656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center.
    Lee SG; Hwang S; Moon DB; Ahn CS; Kim KH; Sung KB; Ko GY; Park KM; Ha TY; Song GW
    Liver Transpl; 2008 Jul; 14(7):935-45. PubMed ID: 18581465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.